Clinical Trial

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

Study acronym: NOVA2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 13 locations 2026-05-07
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07363577
Lead Sponsor LB Pharmaceuticals Inc.
Conditions Schizophrenia
Enrollment 456 participants
Start Date 2026-03-25
Primary Completion 2027-06 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-27